Company news

Amylyx Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 9, 2025

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

January 5, 2025

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

December 3, 2024

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 6, 2024

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

November 3, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

October 16, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

October 14, 2024

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration

August 11, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 7, 2024

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

August 4, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

August 1, 2024

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

July 9, 2024

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

July 8, 2024

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

May 8, 2024

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

May 7, 2024

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

April 9, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

April 7, 2024

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

April 3, 2024

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

March 13, 2024

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

March 7, 2024

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 22, 2024

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

February 14, 2024

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

February 14, 2024

Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

February 7, 2024

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

December 21, 2023

Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

December 3, 2023

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 28, 2023

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

November 27, 2023

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

November 26, 2023

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023

November 1, 2023

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

October 18, 2023

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

October 12, 2023

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control

October 9, 2023

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

October 4, 2023

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting

October 1, 2023

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 9, 2023

Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

July 11, 2023

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

June 22, 2023

Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS

June 14, 2023

Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

May 29, 2023

Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results

May 10, 2023

Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

May 4, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.